The Efficient Circulating Immunoscore Predicts Prognosis of Patients with Advanced Gastrointestinal Cancer

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2022 Jul 12

PMID 35820903

Authors

Yamei Zhao

Yan Tang

Hanlin Qin

Kehai Feng

Changlu Hu

Affiliations

Soon will be listed here.

Abstract

Background: Immunoscore from tumor tissues was initially established to evaluate the prognosis of solid tumor patients. However, the feasibility of circulating immune score (cIS) for the prognosis of advanced gastrointestinal cancers (AGC) has not been reported.

Material And Methods: Peripheral venous blood was collected from 64 untreated AGC patients. We utilized flow cytometry to determine several immune cell subpopulations, including CD8 and CD4 T cells, NK cells, and CD4 + CD25 + CD127 Tregs. The circulating immune score 1 (cIS1) was assessed according to the proportions of CD4, CD8 T cells, and NK cell, whereas circulating immune score 2 (cIS2) was derived from the proportions of CD4, CD8 T cell, and CD4 + CD25 + CD127 Tregs. The prognostic role of cIS for progression-free survival (PFS) and overall survival (OS) was analyzed using Kaplan-Meier curves and Cox multivariate models. Receiver operating characteristic (ROC) curves were depicted to compare the prognostic values of cIS1 and cIS2.

Results: AGC patients with high cIS1(≥ 2) and cIS2(≥ 2) had significantly longer PFS (cIS1: median PFS, 11 vs. 6.7 months, P = 0.001; cIS2: 12 vs. 5.8 months, P < 0.0001) and OS (cIS1: median OS, 12 vs. 7.9 months, P = 0.0004; cIS2: 12.8 vs. 7.4 months, P < 0.0001) than those with low cIS1 and low cIS2. The areas under ROC curves (AUROCs) of cIS1 and cIS2 for OS were 0.526 (95% confidence interval; 95% CI 0.326-0.726) and 0.603 (95% CI 0.427-0.779, P = 0.332), whereas AUROC of cIS2 for PFS was larger than that of cIS1 0.735 (95% CI 0.609-0.837) vs 0.625 (95% CI 0.495-0.743) (P = 0.04)).

Conclusion: The cIS can be applied to predict the prognosis of untreated AGC patients. Compared with cIS1, cIS2 displayed superior prognostic value for PFS prediction.

Citing Articles

Quan X, Ruan L, Zhou H, Gao W, Zhang Q, Zhang C Open Life Sci. 2023; 18(1):20220557.

PMID: 36816803 PMC: 9922058. DOI: 10.1515/biol-2022-0557.

References

Okadome K, Baba Y, Yagi T, Kiyozumi Y, Ishimoto T, Iwatsuki M . Prognostic Nutritional Index, Tumor-infiltrating Lymphocytes, and Prognosis in Patients with Esophageal Cancer. Ann Surg. 2018; 271(4):693-700. DOI: 10.1097/SLA.0000000000002985. View

Zhou W, Deng J, Chen Q, Li R, Xu X, Guan Y . Expression of CD4+CD25+CD127 regulatory T cells and cytokines in peripheral blood of patients with primary liver carcinoma. Int J Med Sci. 2020; 17(6):712-719. PMC: 7085268. DOI: 10.7150/ijms.44088. View

Eriksen A, Sorensen F, Lindebjerg J, Hager H, Christensen R, Kjaer-Frifeldt S . The Prognostic Value of Tumor-Infiltrating lymphocytes in Stage II Colon Cancer. A Nationwide Population-Based Study. Transl Oncol. 2018; 11(4):979-987. PMC: 6039294. DOI: 10.1016/j.tranon.2018.03.008. View

Fan J, Wang L, Chen M, Zhang J, Li J, Song F . Analysis of the expression and prognosis for leukocyte immunoglobulin-like receptor subfamily B in human liver cancer. World J Surg Oncol. 2022; 20(1):92. PMC: 8943947. DOI: 10.1186/s12957-022-02562-w. View

Li X, Yang J . Association of tumor deposits with tumor-infiltrating lymphocytes and prognosis in gastric cancer. World J Surg Oncol. 2022; 20(1):58. PMC: 8883644. DOI: 10.1186/s12957-022-02507-3. View

Knutson K, Disis M . Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005; 54(8):721-8. PMC: 11032889. DOI: 10.1007/s00262-004-0653-2. View

Schantz S, Shillitoe E, Brown B, Campbell B . Natural killer cell activity and head and neck cancer: a clinical assessment. J Natl Cancer Inst. 1986; 77(4):869-75. View

Pernot S, Terme M, Radosevic-Robin N, Castan F, Badoual C, Marcheteau E . Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. Gastric Cancer. 2019; 23(1):73-81. DOI: 10.1007/s10120-019-00983-3. View

Kang D, Chung C, Sun P, Lee D, Lee S, Park D . Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors. Cancer Immunol Immunother. 2021; 71(3):579-588. PMC: 8854239. DOI: 10.1007/s00262-021-03018-y. View

10.

Ahmadvand S, Faghih Z, Montazer M, Safaei A, Mokhtari M, Jafari P . Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients. Cell Oncol (Dordr). 2019; 42(3):343-356. DOI: 10.1007/s13402-019-00430-6. View

11.

Zheng Y, Chen Z, Han Y, Han L, Zou X, Zhou B . Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment. Nat Commun. 2020; 11(1):6268. PMC: 7722722. DOI: 10.1038/s41467-020-20019-0. View

12.

Tang Y, Xie M, Li K, Li J, Cai Z, Hu B . Prognostic value of peripheral blood natural killer cells in colorectal cancer. BMC Gastroenterol. 2020; 20(1):31. PMC: 7006176. DOI: 10.1186/s12876-020-1177-8. View

13.

Mlecnik B, Van den Eynde M, Bindea G, Church S, Vasaturo A, Fredriksen T . Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival. J Natl Cancer Inst. 2017; 110(1). DOI: 10.1093/jnci/djx123. View

14.

Ebinger S, Warschkow R, Tarantino I, Schmied B, Guller U, Schiesser M . Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients: a population-based SEER analysis. Gastric Cancer. 2015; 19(3):723-34. DOI: 10.1007/s10120-015-0541-9. View

15.

Zhang D, He W, Wu C, Tan Y, He Y, Xu B . Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer. Front Immunol. 2019; 10:71. PMC: 6361780. DOI: 10.3389/fimmu.2019.00071. View

16.

Pages F, Mlecnik B, Marliot F, Bindea G, Ou F, Bifulco C . International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018; 391(10135):2128-2139. DOI: 10.1016/S0140-6736(18)30789-X. View

17.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C . Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313(5795):1960-4. DOI: 10.1126/science.1129139. View

18.

Wang B, Li F, Guo L, Lu S, Ma J, Ma Y . Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell. World J Surg Oncol. 2020; 18(1):196. PMC: 7414758. DOI: 10.1186/s12957-020-01970-0. View

19.

Enblad M, Ghanipour L, Cashin P . Prognostic scores for colorectal cancer with peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Hyperthermia. 2018; 34(8):1390-1395. DOI: 10.1080/02656736.2018.1464668. View

20.

Vatandoust S, Price T, Karapetis C . Colorectal cancer: Metastases to a single organ. World J Gastroenterol. 2015; 21(41):11767-76. PMC: 4631975. DOI: 10.3748/wjg.v21.i41.11767. View